Yelena Janjigian, MD
Enriched profileChief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center; holds the Carroll and Milton Petrie Endowed Chair · Memorial Sloan Kettering Cancer Center
Yelena Janjigian is Chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center; holds the Carroll and Milton Petrie Endowed Chair at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 732 publications with 39,120 citations (h-index 68); ClinicalTrials.gov lists 16 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Yelena Janjigian, MD, is Chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center. The public record shows 732 publications with 39,120 citations (h-index 68), centered on Gastric Cancer Management and Outcomes, Esophageal Cancer Research and Treatment, Lung Cancer Treatments and Mutations. It also documents an investigator role on 16 registered clinical trials, industry payments reported by 28 companies, 1 NIH-funded awards (2021–2025).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Gastric Cancer Management and Outcomes
- 16 registered trials on ClinicalTrials.gov
- Open Payments reporting from 28 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 22 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 199.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 16 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
- A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Industry payments
Updated 27 Aug 2026
28 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20258 payments$19,089openpaymentsdata.cms.gov ↗
- AstraZeneca UK LimitedProgram year202511 payments$13,670openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20258 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Proton pump inhibitor51.5%Pantoprazole Sodium66%Omeprazole34%Part D<11 patientsSerotonin-3 Receptor Antagonist24.7%Ondansetron Hcl100%Part D≥18 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2021–2025 per NIH RePORTER. The latest:
- Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatin
Sloan-Kettering Inst Can Research
FY2025$695,700R01CA244233 - Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatin
Sloan-Kettering Inst Can Research
FY2024$660,915R01CA244233 - Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatin
Sloan-Kettering Inst Can Research
FY2023$678,920R01CA244233
Congress activity
Updated 27 Aug 2026
184 congress contributions (2011–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract CT166: A phase II study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in PD-1 refractory gastroesophageal cancer (GEC)
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Molecular Lineages of Sporadic Mismatch Repair-Deficient Colorectal Cancer.
Clinical cancer research
Article2026 - Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal Adenocarcinoma.
JCO precision oncology
Article2026 - Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial.
Nature medicine
Clinical Trial2025 - Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
JCO precision oncology
Article2025
Most-cited works
by citation count (OpenAlex)- 01Comprehensive molecular characterization of gastric adenocarcinomaArticle6,567 citations2014
- 02Tumor mutational load predicts survival after immunotherapy across multiple cancer typesArticle4,411 citations2019
- 03
- 04
- 05OncoKB: A Precision Oncology Knowledge BaseArticle2,725 citations2017
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/yelena-janjigian-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/yelena-janjigian-702123100
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Yelena-Y-Janjigian-16293973
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/memorialsloankettering/posts/yelena-janjigian-is-a-medical-oncologist-who-cares-for-people-with-stomach-cance/10156255900358123
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Instagram
instagram.com/p/DRu40AzExZD
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Other
connection.asco.org/do/path-plenary-q-dr-yelena-janjigian
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connection.asco.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
New York University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Board Certified
Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mskcc.org ↗ - Board Certified
Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Editorial & leadership roles
journal and society appointments- Advisory Board and Selection Committee member
Giants of Cancer Care
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →giantsofcancercare.com ↗
Awards & honors
honors on the public record- 2026 Hematology and Medical Oncology Fellowship Service Award
Memorial Sloan Kettering Cancer Center
2026provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗ - Young Investigator Award
Conquer Cancer, the ASCO Foundation
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →conquer.org ↗ - Career Development Award
Conquer Cancer, the ASCO Foundation
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →conquer.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.weill.cornell.edu ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →audiomedica.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Valerie Rusch, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center